Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).
about
Pasireotide: a novel treatment for patients with acromegalyNeed for improved monitoring in patients with acromegalyThe risks of overlooking the diagnosis of secreting pituitary adenomasEpidemiology of acromegaly: review of population studies.Challenges in the diagnosis and management of acromegaly: a focus on comorbidities.Implementing a screening program for acromegaly in Latin America: necessity versus feasibilityFeatures at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosedThe endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.Efficacy and complications of neurosurgical treatment of acromegaly.Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review.Clinical, quality of life, and economic value of acromegaly disease controlA male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression.Sleep apnea in patients with acromegaly. Frequency, characterization and positive pressure titration.Pulmonary epidermoid carcinoma in a patient with acromegaly: a rare entityIGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.Treatment strategies for acromegaly.The association between biochemical control and cardiovascular risk factors in acromegaly.Growth hormone and its disordersERβ overexpression results in endocrine therapy resistance and poor prognosis in postmenopausal ERα-positive breast cancer patients.Dynamic tests and basal values for defining active acromegaly.Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?Incidence and prevalence of acromegaly in a large US health plan databaseThe multimodal management of GH-secreting pituitary adenomas: predictive factors, strategies and outcomesGrowth Hormone and Treatment Controversy; Long Term Safety of rGH.Nanomedicines in the treatment of acromegaly: focus on pegvisomant.Cost of management of invasive growth hormone-secreting macroadenoma.Excess mortality in acromegaly.No differences in metabolic outcomes between nadir GH 0.4 and 1.0 ng/mL during OGTT in surgically cured acromegalic patients (observational study).Pegvisomant: current and potential novel therapeutic applications.Risk of malignant neoplasms in acromegaly: a case-control study.Excess mortality for patients with residual disease following resection of pituitary adenomas.Acromegaly: presentation, morbidity and treatment outcomes at a single centre.Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefitsPharmacotherapy of obstructive sleep apnea.Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies.Diagnosis of acromegaly: state of the art.Octreotide for acromegaly treatment: a reappraisal.Aggressive tumors and difficult choices in acromegaly.Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.Treatment of acromegaly in the era of personalized and predictive medicine.
P2860
Q26774437-27C1FF2B-A287-429E-8C08-B025F1B15E69Q26783670-2986A95D-BCC8-430B-A9E4-92D8DF47D7F3Q28076665-8BB52FBF-FB25-46D7-82A6-B33BBF911A12Q30244550-84B4203F-9A32-4FC3-AA59-0ECC290E0772Q30249746-1692E9FA-1A42-4CE6-9755-C1713EA86A37Q30251471-AC4ACAFB-DD56-4867-8BA0-255E3FC32A17Q33835825-B8610749-AEE8-4D01-9E6C-79B15323E56AQ34031906-BF266B97-6A06-4EFB-8DF7-BC2205BF3C34Q34981394-2CCFA26E-B85B-4510-ADF8-A59C5A6AC73FQ35097567-48ECDED3-9821-4941-9518-03C2F5C8D85AQ35137675-14B8DC5E-5273-4E4B-8B6F-BC95C2F8C6D8Q35620283-4664CF95-3FC4-4623-BCDE-0A445A48BF1DQ36067300-22524511-ED85-42B2-8584-394D9BDCB57FQ36151365-D7B57CA2-3CAB-4747-806C-4F296E72FD1FQ36202868-B3C69C64-1635-4154-9595-02336759AC65Q36302865-514A4989-03CB-4767-8FED-2204ED57E89AQ36303177-72437AE7-A45A-4987-8114-F18E3B2CB1F8Q36362200-96DE5E27-AB27-4D29-B5BB-E07F253EBC9AQ36524735-729024E7-313A-4ECE-9F01-99DAC8272AECQ36626485-8750EF2D-FE1C-41DB-9586-E67A441143E3Q36845980-1893472A-BABD-44FD-9C7E-3EA0C1D9F4C3Q36874730-ACFDA442-2A57-4664-A3B4-A55F8633DC5BQ36890994-B7B6016F-CFDE-4F77-9CA8-18344C57B227Q36918629-2511C4CC-DA52-4004-8799-23B4C6A8C4A6Q36920317-CF7ABD07-2169-4C7A-9E64-1221CEB19136Q36937812-541B26C8-79F8-4F3E-B249-32427A53453BQ37050111-19BFE1CA-48F9-436C-A454-CBCBE44CAAC3Q37205596-D7CEB8D1-5E18-4FF9-A615-8BDDA6A6E630Q37633543-7712EE12-12A5-4FB3-A1AC-78D3ACDF846CQ37672505-A8052D17-5B3D-4941-AB45-F623E876D97DQ37863050-3C5F2148-18A2-48AC-8FBA-53A88643572AQ37890467-1751F1C4-7032-4801-8FA6-EF6CBA29B5DAQ37980741-B7B2000B-B0D0-45C6-AB28-D4DB86D33F79Q37994293-6C722772-998B-43CF-A37C-B4DBAAEFFF45Q38127391-A18D7E4B-7923-4688-89D1-1E355D891BE7Q38131055-4FFB2CCF-21BF-4AE9-AE3B-ECFA3AE2402AQ38152458-334A1BF4-D860-4FA1-A99B-8F28A7763287Q38167711-2A2D0421-A6CF-466E-9DE0-5398B98BD127Q38233686-866BEDA7-22E2-4E26-B691-FBB033B513EEQ38340014-54E31303-CC9A-4C71-A918-9276783680A8
P2860
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Epidemiology, clinical charact ...... Espanol de Acromegalia, REA).
@en
Epidemiology, clinical charact ...... Espanol de Acromegalia, REA).
@nl
type
label
Epidemiology, clinical charact ...... Espanol de Acromegalia, REA).
@en
Epidemiology, clinical charact ...... Espanol de Acromegalia, REA).
@nl
prefLabel
Epidemiology, clinical charact ...... Espanol de Acromegalia, REA).
@en
Epidemiology, clinical charact ...... Espanol de Acromegalia, REA).
@nl
P2093
P356
P1476
Epidemiology, clinical charact ...... Espanol de Acromegalia, REA).
@en
P2093
Antonio Mestron
Antonio Pico
Basilio Moreno
Cesar Varela
Concha Paramo
Elena Torres
Gabriel Obiols
Irene Halperin
Jose-Antonio Vazquez
Jose-Manuel Gomez
P304
P356
10.1530/EJE.0.1510439
P577
2004-10-01T00:00:00Z